Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

This study tests a new combination treatment for advanced bile duct cancer (cholangiocarcinoma) or gallbladder cancer that has stopped responding to standard chemotherapy. The regimen combines cadonilimab (an immunotherapy drug) with a modified chemotherapy called liposomal irinotecan plus leucovorin and fluorouracil. **You may be eligible if...** - You are between 18 and 75 years old with confirmed advanced bile duct or gallbladder cancer - Your cancer has progressed after or you could not tolerate gemcitabine-based chemotherapy - You have at least one measurable tumor by standard criteria - Your overall health is good (ECOG performance status 0–1) - Your blood counts, liver function, and kidney function meet study requirements **You may NOT be eligible if...** - You have had another cancer in the past 5 years (except treated skin cancer or cervical carcinoma in situ) - You have active HIV, active hepatitis B (high viral load), or hepatitis C - You have severe liver or kidney insufficiency or a recent heart attack - You have uncontrolled fluid around the lungs or in the abdomen (pleural effusion or ascites) - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.